In the originally published article there was an error in the abbreviations for Figure 1. The abbreviation “MEP” was incorrectly defined as “monoethyl phospohate”; this should read “megakaryocytic erythroid progenitor”.
Erratum to: Cytogenetic, Inflammatory, Immunologic, and Infectious Basis for Dysplastic Hematopoeisis
Share this Article
Related Content In Immunotherapy
Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma
touchREVIEWS in Oncology & Haematology. 2023;9(1):Online ahead of journal publication
Cancers of the anal canal are relatively uncommon, and account for less than 1% of all new cancer diagnoses in the UK.1 However, the incidence of these cancers has increased over the past decade, primarily in females, in which they have more than doubled.1 Squamous cell anal carcinoma (SCAC) is the most common type of anal cancer, with adenocarcinomas, neuroendocrine carcinomas […]
New Checkpoint Inhibitors and Immunotherapies for Solid Tumours
touchREVIEWS in Oncology & Haematology. 2021;17(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.17.2.90
The antitumor activity of immune checkpoint inhibotors in various solid and haematologic malignancies has substantially increased immunotherapy implications for cancer. Once only a niche treatment for selected cancers (renal cancer and melanoma), now cancer immunotherapy has become an important option for many patients, even moving into the first-line systemic treatment setting for melanoma, non-small cell […]
Emerging Targeted and Immunotherapies in Cholangiocarcinoma
Oncology & Hematology Review (US). 2019;15(2):71–5
Cholangiocarcinoma is an epithelial malignancy of the biliary system characterized by cholangiocyte differentiation, and its incidence is on the rise. Currently, cholangiocarcinomas are classified by their anatomical location in the biliary system as intrahepatic cholangiocarcinoma, distal cholangiocarcinoma, or hilar cholangiocarcinoma. Since 2010, the standard of care in all advanced, inoperable biliary tract cancers has been combination […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!